鱼跃医疗
(002223)
| 流通市值：334.70亿 | | | 总市值：356.88亿 |
| 流通股本：9.40亿 | | | 总股本：10.02亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,435,873,177.34 | 7,565,819,017.28 | 6,027,852,090.96 | 4,307,611,897.68 |
| 营业收入 | 2,435,873,177.34 | 7,565,819,017.28 | 6,027,852,090.96 | 4,307,611,897.68 |
| 二、营业总成本 | 1,816,105,564.51 | 5,947,065,140.88 | 4,578,931,808.83 | 3,182,191,111.21 |
| 营业成本 | 1,210,554,322.86 | 3,772,269,938.71 | 3,005,841,561.23 | 2,151,188,718.65 |
| 税金及附加 | 22,709,209.4 | 74,424,745.76 | 58,577,803.51 | 41,054,467.23 |
| 销售费用 | 362,944,479.94 | 1,361,398,321.47 | 930,620,028.23 | 613,852,772.29 |
| 管理费用 | 102,042,045.73 | 428,230,197.9 | 310,225,370.77 | 207,785,069.62 |
| 研发费用 | 156,329,663.86 | 546,683,621.93 | 405,052,780.76 | 269,617,925.64 |
| 财务费用 | -38,474,157.28 | -235,941,684.89 | -131,385,735.67 | -101,307,842.22 |
| 其中:利息费用 | 562,486.15 | 20,727,024.98 | 17,336,958.12 | 17,278,182.51 |
| 其中:利息收入 | 47,533,147.99 | 237,918,841.43 | 166,913,113.56 | 115,157,364.09 |
| 加:公允价值变动收益 | - | - | - | 107,890.41 |
| 加:投资收益 | 764,972.84 | 23,206,208.79 | 21,502,304.43 | 21,273,000.01 |
| 资产处置收益 | -75,696.74 | 6,161,857.24 | 5,338,234.92 | 5,319,774.45 |
| 资产减值损失(新) | -92,792.72 | -46,990,377.29 | -6,423,745.23 | -5,299,408.42 |
| 信用减值损失(新) | -23,124,867.68 | -21,075,478.18 | -33,295,316.29 | -37,224,134.66 |
| 其他收益 | 139,661,777.6 | 351,524,971.91 | 317,209,325.12 | 178,451,529.82 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 736,901,006.13 | 1,931,581,058.87 | 1,753,251,085.08 | 1,288,049,438.08 |
| 加:营业外收入 | 815,437.43 | 5,047,708.19 | 4,124,944.65 | 2,300,876.76 |
| 减:营业外支出 | 617,028.34 | 3,800,215.94 | 2,230,909.83 | 1,046,686.39 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 737,099,415.22 | 1,932,828,551.12 | 1,755,145,119.9 | 1,289,303,628.45 |
| 减:所得税费用 | 113,916,798.46 | 128,562,201.92 | 221,715,279.81 | 166,409,836.28 |
| 六、净利润 | 623,182,616.76 | 1,804,266,349.2 | 1,533,429,840.09 | 1,122,893,792.17 |
| 持续经营净利润 | 623,182,616.76 | 1,804,266,349.2 | 1,533,429,840.09 | 1,122,893,792.17 |
| 归属于母公司股东的净利润 | 624,758,641.94 | 1,805,700,655.26 | 1,531,593,657.16 | 1,120,197,133.35 |
| 少数股东损益 | -1,576,025.18 | -1,434,306.06 | 1,836,182.93 | 2,696,658.82 |
| (一)基本每股收益 | 0.63 | 1.81 | 1.54 | 1.12 |
| (二)稀释每股收益 | 0.63 | 1.81 | 1.54 | 1.12 |
| 八、其他综合收益 | -53,795,499.78 | 157,085,418.17 | 3,443,387.87 | -396,233.17 |
| 归属于母公司股东的其他综合收益 | -54,873,702.36 | 158,478,569.91 | 3,561,016.34 | 142,688.72 |
| 九、综合收益总额 | 569,387,116.98 | 1,961,351,767.37 | 1,536,873,227.96 | 1,122,497,559 |
| 归属于母公司股东的综合收益总额 | 569,884,939.58 | 1,964,179,225.17 | 1,535,154,673.5 | 1,120,339,822.07 |
| 归属于少数股东的综合收益总额 | -497,822.6 | -2,827,457.8 | 1,718,554.46 | 2,157,736.93 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-26 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |